Vivek Subbiah: Lurbinectedin was approved for Small cell Lung in USA and now is also approved in Canada, Australia, Singapore, the United Arab Emirates, Qatar, South Korea, Ecuador, Mexico, Israel and Switzerland.
Quoting Vivek Subbiah, Chief of Early-Phase Drug Development, on Twitter:
“Final free version just published In European Journal of Cancer for your Friday reading
Lurbinectedin was approved for Small cell Lung in USA & now is also approved in Canada, Australia, Singapore, the United Arab Emirates, Qatar, South Korea, Ecuador, Mexico, Israel & Switzerland
We also showed results of other cohorts of this basket trial showing anti-tumor activity in
Ewing sarcoma, leading to inclusion in the National Comprehensive Cancer Network guidelines
Germline BRCA1/2 metastatic breast cancer.
This paper reports on Safety of approved dose in 554 patients with advanced solid tumors
Most common toxicity was transient and reversible myelosuppression
Non-hematological events were mostly mild/moderate.”
For the article click here.
Source: Vivek Subbiah/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023